Section of Neuroendocrinology of Obesity, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-1613, USA.
J Endocrinol Invest. 2012 May;35(5):541-6. doi: 10.3275/8411. Epub 2012 May 8.
Approximately 215,000 people younger than 20 yr of age, or 1 in 500 children and adolescents, had diabetes in the United States in 2010--and the incidence is rising. We still have insufficient knowledge about the precise mechanisms leading to the autoimmune mediated β-cell destruction in Type 1 diabetes, and the β-cell failure associated with insulin resistance in Type 2 diabetes. Long-term complications are similar: micro- and macrovascular disease occurs prematurely and presents an enormous burden on affected individuals, often as early as in middle age. In Type 1 diabetes, technological advances have clearly improved blood glucose management, but chronic peripheral over-insulinization remains a problem even with the most advanced systems. Thus, in Type 1 diabetes our research must focus on 1) finding the stimulus that ignites the immune response and 2) developing treatments that avoid hyperinsulinemia. In Type 2 diabetes in youth, the challenges start much earlier: most young patients do not even benefit from existing therapies due to non-compliance. Therefore, prevention of Type 2 diabetes and improvement of compliance, especially with non-pharmacological interventions, are the greatest challenges.
2010 年,美国约有 21.5 万名 20 岁以下的青少年患有糖尿病,占儿童和青少年总数的 1/500,且发病率还在上升。我们对导致 1 型糖尿病中自身免疫介导的β细胞破坏的确切机制以及与 2 型糖尿病相关的胰岛素抵抗导致的β细胞衰竭,仍知之甚少。长期并发症相似:微血管和大血管疾病提前发生,给受影响的个人带来巨大负担,往往早在中年就出现这种情况。在 1 型糖尿病中,技术进步显然改善了血糖管理,但即使是最先进的系统,慢性外周胰岛素过度分泌仍然是一个问题。因此,在 1 型糖尿病中,我们的研究必须集中在以下两个方面:1)寻找引发免疫反应的刺激因素,2)开发避免高胰岛素血症的治疗方法。在青少年 2 型糖尿病中,挑战更早开始:由于不遵医嘱,大多数年轻患者甚至无法从现有的治疗中获益。因此,预防 2 型糖尿病和提高患者的依从性,尤其是通过非药物干预,是最大的挑战。